Improving survival and limiting toxicity: Latest advances in treating human epidermal growth factor receptor 2 overexpressing breast cancer

Therapeutic Advances in Medical Oncology

Volumn 4, Issue 3, 2012, Pages 139-147

  Abramson, Vandana G ^a   Mayer, Ingrid A ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

breast cancer; HER2 overexpressing; human epidermal growth factor receptor 2; lapatinib; pertuzumab; trastuzumab; trastuzumab emtansine

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; EVEROLIMUS; FLUOROURACIL; LAPATINIB; LETROZOLE; NAVELBINE; PACLITAXEL; PERTUZUMAB; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ADVANCED CANCER; BRAIN METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOXICITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; LIVER FUNCTION TEST; LIVER TOXICITY; MULTICENTER STUDY (TOPIC); NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84864490937     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834012440834     Document Type: Review

References (31)

1. Baselga J. (2001) Clinical trials of Herceptin(R) (trastuzumab). Eur J Cancer 37(Suppl. 1): 18–24.
2. Baselga J. Bradbury I. Eidtmann H. Di Cosimo S. Aura C. de Azambuja E. et al. (2010 a) First results of the NeoALTTO trial (BIG 01-06 / EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. Cancer Res 70(Suppl. 2): 82s, abstract S3–3.
3. Baselga J. Gelmon K.A. Verma S. Wardley A. Conte P. Miles D. et al. (2010 b) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28: 1138–1144.
4. Baselga J. Cortes J. Kim S. Im S. Hegg R. Im Y. et al. (2011) Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. NEJM 366: 109–119.
5. Blackwell K.L. Burstein H.J. Storniolo A.M. Rugo H. Sledge G. Koehler M. et al. (2010) Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28: 1124–1130.
6. Burstein H.J. Kuter I. Campos S.M. Gelman R.S. Tribou L. Parker L.M. et al. (2001) Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19: 2722–2730.
7. Chang J.C.N. Mayer I.A. Forero-Torres A. Nanda R. Goetz M.P. Rodriguez A.A. et al. (2011) TBCRC 006: a multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer. J Clin Oncol 29(Suppl.): abstract 505.
8. Di Leo A. Gomez H. Aziz Z. Zvirbule Z. Arbushites M. Oliva C.R. et al. (2007) Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: a phase III randomized, double-blind study of 580 patients. Proc Am Soc Clin Oncol 25(18 Suppl.): 34s.
9. Dowsett M. Ebbs S.R. Dixon J.M. Skene A. Griffith C. Boeddinghaus I. et al. (2005) Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer – a study from the IMPACT trialists. J Clin Oncol 23: 2477–2492.
10. Dowsett M. Smith I.E. Ebbs S.R. Dixon J.M. Skene A. Griffith C. et al. (2003) Greater Ki 67 response after 2 weeks neoadjuvant treatment with anastrozole (A) than with tamoxifen (T) or anastrozole plus tamoxifen (C) in the IMPACT trial: a potential predictor of relapse-free survival. Breast Cancer Res Treat 82(Suppl. 1): S6.
11. Ellis P.A. Barrios C.H. Im Y. Patre M. Branle F. Perez E.A. et al. (2011) MARIANNE: a phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatmetn of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC). J Clin Oncol 29(Suppl.): abstract TPS 102.
12. Geyer C.E. Forster J. Lindquist D. Chan S. Romieu C.G. Pienkowski T. et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733–2743.
13. Gianni L. Eiermann W. Semiglazov V. Manikhas A. Lluch A. Tjulandin S. et al. (2010 a) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375: 377–384.
14. Gianni L. Pienkowski T. Im Y-H. Roman L. Tseng L-M. Liu M-C. et al. (2010 b) Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study (‘NeoSphere’). Cancer Res 70(Suppl. 2):82s, abstract S3-2.
15. Gomez H.L. Doval D.C. Chavez M.A. Ang P.C. Aziz Z. Nag S. et al. (2008) Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26: 2999–3005.
16. Howell A. Cuzick J. Baum M. Buzdar A. Dowsett M. Forbes J.F. et al. (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365: 60–62.
17. Krop I.E. LoRosso P. Miller K.D. Modi S. Yardley D. Rodriguez G. et al. (2009) A phase II study of trastuzumab-DM1 (T-DM1), a novel HER 2 antibody-drug conjugate, in patients previously treated with lapatinib, trastuzumab, and chemotherapy. Cancer Res 69(24 Suppl.): abstract 5090.
18. Kummar S. Kinders R. Rubinstein L. Parchment R.E. Murgo A.J. Collins J. et al. (2007) Compressing drug development timelines in oncology using phase ‘0’ trials. Nat Rev Cancer 7: 131–139.
19. Lin N.U. Carey L.A. Liu M.C. Younger J. Come S.E. Ewend M. et al. (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26: 1993–1999.
20. Perez E. Dirix L. Kocsis J. Gianni L. Lu J. Vinholes J. et al. (Oct 2010) Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: preliminary results of a randomized, multicenter, open-label phase 2 study. ESMO Meeting, Milan, Italy, abstract LBA3.
21. Piccart-Gebhart M.J. Procter M. Leyland-Jones B. Goldhirsch A. Untch M. Smith I. et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659–1672.
22. Romond E.H. Perez E.A. Bryant J. Suman V.J. Geyer C.E. Jr Davidson N.E. et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673–1684.
23. Rusnak D.W. Lackey K. Affleck K. Wood E.R. Alligood K.J. Rhodes N. et al. (2001) The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1: 85–94.
24. Scaltriti M. Rojo F. Ocana A. Anido J. Guzman M. Cortes J. et al. (2007) Expression of p95HER2, a truncated form of the HER 2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99: 628–638.
25. Slamon D.J. Eiermann W. Robert N. Pienkowski T. Martin M. Rolski J. et al. (Dec 2009) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC -> T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC -> TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 Study. San Antonio Breast Cancer Symposium, Texas, USA, 2009, abstract 64.
26. Smith I.E. Dowsett M. Ebbs S.R. Dixon J.M. Skene A. Blohmer J.U. et al. (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23: 5108–5116.
27. Smith I. Procter M. Gelber R.D. Guillaume S. Feyereislova A. Dowsett M. et al. (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369: 29–36.
28. Untch M. Loibl S. Bischoff J. Eidtmann H. Kaufmann M. Blohmer J.U. et al. (Dec 2010) Lapatinib vs. trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: primary efficacy endpoint analysis of the Gueparquinto study (GBG 44). San Antonio Breast Cancer Symposium, Texas, USA, 2010, abstract S3-1.
29. Vogel C.L. Cobleigh M.A. Tripathy D. Gutheil J.C. Harris L.N. Fehrenbacher L. et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719–726.
30. Vogel C.L. Burris H.A. Limentani S. Borson R. O'Shaughnessy J. Vukelja S. et al. (2009) A phase II study of trastuzumab-DM1 (TDM1), a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer: final results. J Clin Oncol 27(Suppl.): 15s.
31. Widdison W.C. Wilhelm S.D. Cavanagh E.E. Whiteman K.R. Leece B.A. Kovtun Y. et al. (2006) Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 49: 4392–4408.